Screening and Validation of Serum Protein Biomarkers for Early Diagnosis of Gastric Cancer (NCT07096752) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Screening and Validation of Serum Protein Biomarkers for Early Diagnosis of Gastric Cancer
1,200 participantsStarted 2025-08-01
Plain-language summary
This study focuses on the discovery of protein biomarkers for the early diagnosis of gastric cancer and the development of corresponding detection methods. By employing advanced mass spectrometry-based proteomic technologies, the investigators conducted an in-depth analysis of a large cohort of clinical samples to identify specific protein biomarkers capable of accurately distinguishing gastric cancer patients from healthy individuals. The findings from this research are expected to facilitate the development of novel non-invasive or minimally invasive diagnostic approaches, thereby improving early detection, enhancing patient prognosis, and increasing survival rates.
Who can participate
Age range18 Years – 95 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female, aged ≥18 and ≤95 years.
✓. Histopathologically confirmed gastric cancer, as defined by the 2024 edition of the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Gastric Cancer.
✓. No prior anti-tumor treatment (including radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
✓. Availability of complete clinicopathological data and follow-up information.
✓. Male or female, aged ≥18 and ≤95 years.
✓. Histopathologically confirmed absence of gastric cancer.
✓. Diagnosis consistent with precancerous gastric lesions as defined by the American Society for Gastrointestinal Endoscopy (ASGE, 2015 edition).
✓. Availability of complete clinicopathological data and follow-up information.
Exclusion criteria
✕. History of prior malignancy or cancer treatment.
What they're measuring
1
Diagnostic Performance of the Serum Protein Biomarker-Based Model for Gastric Cancer